Molnupiravir

• Generic versions of Pfizer’s Paxlovid to be sold in low-income countries for $25 or less

  A generic course of molnupiravir is expected to cost about $20 in poorer nations, compared with the roughly $700 per course Merck is charging the United States.

  Health

  May 12, 2022
  
• Newly approved COVID-19 pills come with a catch. Here’s what you should know

  U.S. regulators authorized Pfizer's pill, Paxlovid, and Merck's molnupiravir this week.

  Health

  Dec 26, 2021
  
• Advertisement
• Merck’s antiviral COVID-19 pill approved by U.S. FDA for at-home use

  Merck's drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce COVID-19 hospitalizations and deaths by around 30 per cent.

  World

  Dec 23, 2021
• Advertisement
• Merck to make its COVID-19 antiviral pill in Canada, company announces

  Merck has reached an agreement with an Ontario pharmaceutical company to make its oral COVID-19 treatment, molnupiravir, in Canada, officials said Monday.

  Health

  Dec 6, 2021
• Canada secures orders of Merck, Pfizer COVID-19 antiviral pills

  Canada has announced it has signed purchasing agreements with Pfizer and Merck for their COVID-19 antiviral pills designed to treat the virus.

  Health

  Dec 3, 2021
• Merck’s COVID-19 pill reduces hospitalization, death risk by 30%, company says

  The company said the data on the drug molnupiravir had been submitted to the U.S. Food and Drug Administration ahead of a meeting of its expert advisers on Tuesday.

  Health

  Nov 26, 2021
• New Pfizer COVID-19 pill reduces hospital, death risk by 90%, company says

  Pfizer's pill to treat COVID-19 reduces the risk of hospitalization and death by nearly 90 per cent, the company said Friday when it released preliminary results.

  Health

  Nov 5, 2021
• U.K. approves Merck antiviral pill to treat COVID-19

  The U.K. is the first country to approve Merck's molnupiravir antiviral treatment for COVID-19.

  Health

  Nov 4, 2021